The biosimilar program advancement and strengthened balance sheet provide near-term runway into Q3 2026, but the company remains deeply unprofitable with a large accumulated deficit. Traders should monitor the next FDA interaction (planned 2026 Type 2b meeting) and upcoming analytical data completion as key catalysts. Dilution risk remains elevated given capital structure and history of warrant and note adjustments.
Price Chart
Executive Summary
AEON Biopharma reported financial results for 2025, highlighted by a net loss of $39.2 million and a cash balance of $3.0 million as of year-end. The company emphasized progress in its ABP-450 biosimilar program, including positive FDA feedback and analytical similarity to BOTOX®, alongside a $6 million PIPE financing and debt reduction. However, the financials show significant losses and a stockholders' deficit of $55 million.
Key Financial Metrics
Key Facts
- Reported net loss of $39.2 million for 2025, compared to net income of $42.0 million in 2024
- Cash and cash equivalents were $3.0 million as of December 31, 2025, with liquidity expected into Q3 2026
- Completed $6 million PIPE financing and note exchange, reducing debt by over 90%
- Positive FDA Type 2a meeting feedback on ABP-450 biosimilar development program
- Appointed John Bencich as CFO with 25+ years of capital markets experience
Financial Impact
Net loss of $39.2 million in 2025; stockholders' deficit increased to $55.0 million; $6 million in new financing
Risk Factors
- Continued operating losses and stockholders' deficit of $55 million
- High reliance on future financing to sustain operations beyond Q3 2026
- Regulatory risk in advancing ABP-450 through FDA approval process
- Complex capital structure with derivative and warrant liabilities totaling over $18 million
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265006 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 8-K | $0.2399 | awaiting T+5 | — | $0.2400 (+0.04%) |
Sep 30, 2026 26d ago | 8-K | $0.3000 $0.3110 | ▲ +3.67% | ▲ +1.75% | $0.2400 (−20.00%) |
Aug 21, 2026 9w ago | 3 | $0.1974 $0.2959 | ▲ +49.90% | ▲ +49.43% | $0.2400 (+21.58%) |
Aug 19, 2026 9w ago | Press Release | $0.1980 $0.2515 | ▲ +27.02% | ▲ +27.41% | $0.2400 (+21.21%) |
Aug 12, 2026 10w ago | Press Release | $0.2706 $0.1931 | ▼ −28.64% | ▼ −26.68% | $0.2400 (−11.31%) |
Jul 23, 2026 13w ago | 8-K | $0.2507 $0.2552 | ▼ −1.79% | ▼ −1.42% | $0.2400 (+4.27%) |
Jul 15, 2026 14w ago | 8-K | $0.2974 $0.2600 | ▲ +12.58% | ▲ +10.91% | $0.2400 (+19.30%) |
Jul 15, 2026 14w ago | 424B4 | $0.2997 $0.2752 | ▲ +8.17% | ▲ +7.19% | $0.2400 (+19.92%) |
Jul 14, 2026 14w ago | EFFECT | $0.3570 $0.2890 | ▲ +19.05% | ▲ +17.75% | $0.2400 (+32.77%) |
Jul 9, 2026 15w ago | S-1/A | $0.5027 $0.2974 | ▲ +40.84% | ▲ +40.71% | $0.2400 (+52.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers